JP Morgan Chase
STOK icon

JP Morgan Chase’s Stoke Therapeutics STOK Stock Holding History

JP Morgan Chase’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-8,300
Closed -$198K – 5760
2020
Q2 		$198K Buy
+8,300
New +$197K ﹤0.01% 4263

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

JP Morgan Chase's STOK Position: Q1 2026 in Review

JP Morgan Chase reduced its Stoke Therapeutics (STOK) stake by 4.5% in Q1 2026, selling an estimated $409K and leaving 265,473 shares worth $8.43M. The position accounts for ﹤0.01% of the portfolio, ranked #2838.

JP Morgan Chase first reported a position in STOK in Q3 2019 and has held it in 27 quarters since. The position peaked at $8.82M in Q4 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • JP Morgan Chase held 265,473 shares of Stoke Therapeutics worth $8.43M as of Q1 2026.
  • JP Morgan Chase sold 12,457 Stoke Therapeutics shares in Q1 2026, an estimated $409K.
  • Stoke Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2838 holding.
  • JP Morgan Chase first reported a position in Stoke Therapeutics in Q3 2019 and has held it in 27 quarters since.
  • JP Morgan Chase's Stoke Therapeutics position peaked at $8.82M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.